However, aggressive treatment for elevated PTH after KTx may improve clinical outcomes, as several reports have demonstrated that therapeutic intervention for normocalcemic hyperparathyroidism in non-CKD patients can reduce complication risks, including bone lesions [45, 46], nephrolithiasis [47, 48], cardiovascular disease [34], and reduced quality of life [49]. The gene discussed is PTH; the disease is cardiovascular disorder.